Table 2.
Patients enrolled and treatment outcomes
| Parameters | Test drug and study site | |||||
|---|---|---|---|---|---|---|
| Chloroquine (CQ) | Artemether-lumefantrine (AL) | |||||
| Debrezeit | Nazareth | Total | Debrezeit | Nazareth | Total | |
| Total patients enrolled | 27 | 44 | 71 | 36 | 52 | 88 |
| Follow-up completed | 21 (77.8%) | 36 (81.8%) | 57 (80.3%) | 30 (83.3%) | 45 (86.5%) | 75 (85.2%) |
| Loss and withdrawal | 6 (22.2%) | 8 (18.2%) | 14 (19.7%) | 6 (16.7%) | 7 (13.5%) | 13 (14.8%) |
| Treatment success | 18 (85.7%) | 34 (94.4%) | 52 (91.2%) | 23 (76.7%) | 33 (73.3%) | 56 (74.7%) |
| Treatment failure | 3 (14.3%) | 2 (5.6%) | 5 (8.8%) | 7 (23.3%) | 12 (26.7%) | 19 (25.3%) |
| Day of treatment failure | ||||||
| Before day 21 | 0 | 0 | 0 | 0 | 1 (8.3%) | 1 (5.3%) |
| Day 21 | 0 | 0 | 0 | 3 (42.8%) | 4 (33.3%) | 7 (36.8%) |
| Day 28 | 3 (100%) | 2 (100%) | 5 (100%) | 4 (57.2%) | 7 (58.3%) | 11 (57.9%) |
| Blood level of CQ in treatment failure cases | ||||||
| < 100 ng/mL (32–64 ng/mL) | 1 (33.3%) | 2 (100%) | 3 (60%) | ND | ND | |
| > 100 ng/mL (256–320 ng/mL) | 2 (66.6%) | 0 | 2 (40%) | ND | ND | |
ND = not done.